NCT00332696 - Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Peritoneal NeoplasmsIntestinal ObstructionCarcinomatosis

Interventions

DRUG

Octreotide LAR

Octreotide long-acting release (LAR) 30 mg intramuscular injection.

DRUG

Octreotide (Immediate release)

Immediate-release Octreotide supplied in 100 µg/mL ampules.

DRUG

methylprednisolone

methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections).

DRUG

Placebo

Physiologic saline solution

Trial Locations (1)

Novartis Investigative Site, Créteil